These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 29384220)
1. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway. Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220 [TBL] [Abstract][Full Text] [Related]
2. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Vucicevic L; Misirkic M; Janjetovic K; Vilimanovich U; Sudar E; Isenovic E; Prica M; Harhaji-Trajkovic L; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V Autophagy; 2011 Jan; 7(1):40-50. PubMed ID: 20980833 [TBL] [Abstract][Full Text] [Related]
3. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540 [TBL] [Abstract][Full Text] [Related]
4. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. Acharya B; Chaijaroenkul W; Na-Bangchang K J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818 [TBL] [Abstract][Full Text] [Related]
5. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885 [TBL] [Abstract][Full Text] [Related]
6. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811 [TBL] [Abstract][Full Text] [Related]
7. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression. Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538 [TBL] [Abstract][Full Text] [Related]
9. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225 [TBL] [Abstract][Full Text] [Related]
10. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376 [TBL] [Abstract][Full Text] [Related]
11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X Gene; 2019 May; 698():50-60. PubMed ID: 30822475 [TBL] [Abstract][Full Text] [Related]
12. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583 [TBL] [Abstract][Full Text] [Related]
14. Wogonin induces cross-regulation between autophagy and apoptosis via a variety of Akt pathway in human nasopharyngeal carcinoma cells. Chow SE; Chen YW; Liang CA; Huang YK; Wang JS J Cell Biochem; 2012 Nov; 113(11):3476-85. PubMed ID: 22689083 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923 [TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Zhao X; Zhang C; Zhou H; Xiao B; Cheng Y; Wang J; Yao F; Duan C; Chen R; Liu Y; Feng C; Li H; Li J; Dai R Oncotarget; 2016 Dec; 7(51):85492-85501. PubMed ID: 27863431 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway. Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421 [TBL] [Abstract][Full Text] [Related]
18. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590 [TBL] [Abstract][Full Text] [Related]
19. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. Wang F; Wang Q; Zhou ZW; Yu SN; Pan ST; He ZX; Zhang X; Wang D; Yang YX; Yang T; Sun T; Li M; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():537-60. PubMed ID: 25632222 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S Life Sci; 2022 May; 296():120427. PubMed ID: 35218764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]